VFA
STML

Virtus Fund Advisers’s Stemline Therapeutics, Inc. STML Stock Holding History

Virtus Fund Advisers’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$374K Buy
+23,958
New +$320K ﹤0.01% 378
2014
Q3 		– Sell
-985
Closed -$14K – 2227
2014
Q2 		$14K Buy
+985
New +$15.1K ﹤0.01% 2648

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Virtus Fund Advisers's STML Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Stemline Therapeutics, Inc. (STML) in Q4 2017: 23,958 shares worth $374K. The stake represents ﹤0.01% of the portfolio and ranks #378 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in STML as recently as Q2 2014.

Virtus Fund Advisers first reported a position in STML in Q2 2014 and has held it in 2 quarters since. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

  • Virtus Fund Advisers held 23,958 shares of Stemline Therapeutics, Inc. worth $374K as of Q4 2017.
  • Stemline Therapeutics, Inc. was a new Virtus Fund Advisers position in Q4 2017.
  • Stemline Therapeutics, Inc. made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #378 holding.
  • Virtus Fund Advisers first reported a position in Stemline Therapeutics, Inc. in Q2 2014 and has held it in 2 quarters since.
  • 80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.